Drugs / Levobetaxolol
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BETAXON | — | 2006-09-28 | fda.gov ↗ |
| Approved | US (FDA) | BETAXON | — | 2000-02-23 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02617459 | Jan 2019 → Jul 2021 | ocular hypertension, open-angle glaucoma | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00061516 | Jan 2003 → Feb 2006 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levobetaxolol | “BETAXON (levobetaxolol HCl)” NCT00061516 ↗ |
| Known as | AL-1577A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201274 ↗ |
| Known as | BETAXON | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00061516 ↗ |
| Known as | levobetaxolol HCl | “BETAXON (levobetaxolol HCl)” NCT00061516 ↗ |
| Known as | LEVOBETAXOLOL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201274 ↗ |
| Action | Inhibit | “Beta-1 adrenergic receptor antagonist” CHEMBL1201274 ↗ |
| Modality | Small molecule | — CHEMBL1201274 ↗ |
| Route | Other | “Levobetaxolol eye drops” NCT02617459 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL1201274 ↗ |